|
Jun 20
|
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
|
|
May 15
|
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
|
|
Feb 11
|
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
|
|
Aug 30
|
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
|
|
Dec 5
|
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
|